SCHEMBL5913810

SCHEMBL5913810

CN(c1ccnc(NC2CCN(C(=O)CNC(=O)OC(C)(C)C)CC2)n1)c1ccnc(-c2ccccc2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 6/20 0.48
▸ SIGMAR1 Q99720 1/20 0.44
▸ ACACB O00763 2/20 0.42
▸ ACACA Q13085 2/20 0.42
▸ JUN P05412 5/20 0.41
▸ MAPK9 P45984 5/20 0.41
▸ CKS1B P61024 3/20 0.41
▸ SKP1 P63208 3/20 0.41
▸ SKP2 Q13309 3/20 0.41
▸ MAPK10 P53779 2/20 0.41
▸ PTK2 Q05397 1/20 0.41
▸ USP30 Q70CQ3 2/20 0.40
▸ FNTA P49354 1/20 0.40
▸ FNTB P49356 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CDK2 P24941 4/20 0.39
▸ MAPK14 Q16539 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5914134 0.84 MAPK8 (0.44) MAPK8JUNMAPK9MAPK10PTK2
SCHEMBL5913964 0.82 MAPK8 (0.44) MAPK8JUNMAPK9MAPK10PTK2
SCHEMBL5914214 0.81 MAPK8 (0.41) MAPK8JUNMAPK9MAPK10PTK2
SCHEMBL5914206 0.81 MAPK8 (0.41) MAPK8JUNMAPK9MAPK10PTK2
SCHEMBL5913814 0.80 USP30 (0.36) MAPK8ACACBACACAJUNMAPK9
SCHEMBL5264835 0.79 ACACB (0.44) ACACBACACACKS1BSKP1SKP2
SCHEMBL5266019 0.75 MAPK8 (0.54) MAPK8MAPK9CKS1BSKP1SKP2
SCHEMBL5341690 0.74 USP30 (0.48) CKS1BSKP1SKP2USP30ALDH1A1
SCHEMBL5913836 0.73 ALDH1A1 (0.48) USP30ALDH1A1CDK2MAPK14
SCHEMBL5914425 0.72 IKBKB (0.47) MAPK8PTK2CDK2MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060069110-A1 Substituted heterocyclic compounds and methods of use AMGEN INC. 2006-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069110-A1 Substituted heterocyclic compounds and methods of use MAPT, MYLK2, IAPP MAPK8 1760/4885SIGMAR1 3655/4885ACACB 2217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback